CDXS

Codexis Inc. (CDXS) | Rumor.io

Codexis

CDXS

Attention (50-day avg)0%

Attention rank (50-day avg)#2,677

Bullish sentiment (50-day avg)84%

Price to earnings ratio-2.72

Market capitalization148.9M

Earnings per share-0.33

Dividend yield (TTM)—

Revenue (annual)70.4M

Net income (annual)-44M

Social

What share of all stock conversation is about CDXS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 11

Codexis, Inc. ($CDXS) reported Q2 2026 revenue of $14.9 million, with product revenue rising to $13.2 million and legacy R&D service revenue declining.
The company expects its existing cash to be sufficient to fund operations through the end of 2028, including the build-out of a GMP production facility.
Codexis is in advanced negotiations for a long-term commercial contract with a CDMO, which could be a significant announcement by the end of the year.

Generated by AI

Sentiment

Of the messages about CDXS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	50%	75% -10.71	84.01% -0.67
Bearish	100%	50%	25% +10.71	15.99% +0.67

Bullish· Jun 18

Codexis, Inc. ($CDXS) has been given an $11 price target by Cantor Fitzgerald, indicating a potential double or triple in value.
The company is considered a "lottery ticket" with a high potential for growth, making it a must-own stock for investors.
A takeover or acquisition of Codexis, Inc. is expected, which could drive up the stock price and result in significant returns for investors.

Bearish· Mar 12

$CDXS is expected to fall to around $2.25, with some investors selling at $66.
The stock's price action is not real, with market makers artificially keeping the bid/ask fixed, preventing any meaningful movement.
Shorts are being squeezed, with some investors facing potential losses if they don't cover their positions ASAP, and others being warned of a "big story" or "huge failure" in the near future.

Generated by AI

Topics

Of the messages about CDXS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	94.44%	94.74%	55.46%
Technical Analysis	50%	5.56%	5.26%	28.65%
Earnings	0%	0%	0%	1.7%
Analysts	0%	0%	0%	7.23%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	6.95%

Earnings· May 10

Codexis, Inc. ($CDXS) beats earnings per share (EPS) loss estimates by $0.07.
$CDXS beats revenue estimates.
Codexis, Inc. ($CDXS) reports a positive earnings surprise.

Announcements· Mar 20

Codexis, Inc. (CDXS) announces partnership with NASDAQ:NXXT to scale intelligence across operations.
NASDAQ:NXXT aligns infrastructure with AI, driving growth and supporting energy demand, in a move that benefits CDXS.
CDXS is mentioned as a partner in NASDAQ:NXXT's growth, with both companies working together on infrastructure systems.

Generated by AI

Community

Of the messages about CDXS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	55.56%	48.39%	35.28%
Newcomers	0%	44.44%	51.61%	64.72%

Regulars· Aug 11

Codexis has completed tech transfers for all three CDMO contracts, with one in advanced negotiations for a long-term commercial partnership.
The company expects its existing cash to fund operations through 2028, including the build-out of a GMP production facility, and is optimistic about the potential for milestone payments from the lead contract.
Despite concerns about the lack of tangible revenue-driving deals, Codexis' product revenue surged in Q2 2026, masking a collapse in legacy R&D service revenue.

Newcomers· Jul 24

Newcomers to discussing Codexis, Inc. (CDXS) are focused on the company's recent stock offering, which priced 16.7 million common shares at $1.50 per share, raising approximately $23.1 million in net proceeds.
Some newcomers are concerned about the company's potential need to do a reverse split within the next six months, citing the large amount of shares issued in the offering.
Others are expressing skepticism about the company's recovery prospects, with some even predicting a potential decline in the stock price, while others are questioning the timing of the announcement.

Generated by AI

REDWOOD CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced an agreement with a pioneering siRNA drug innovator to explore stereo-defined fragment synthesis using its ECO Synthesis® Manufacturing Platform. The agreement builds on advances presented at TIDES USA 2026, where for the first time, Codexis demonstrated full-length siRNA synthesis with precise cont

2d agoYahoo Finance Australia

Codexis at Cantor conference: enzymatic RNA manufacturing gains ground

19d agoInvesting.com

Codexis to Participate in Cantor Global Healthcare Conference 2026

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York. Management will participate in a fireside chat on Thursday, September 10, 2026, at 9:45 am ET. A live webcast of the event will be available in the Investor Relatio

1mo agoYahoo Finance

Codexis (CDXS) Q2 2026 Earnings Call Transcript

Motley Fool Press Release.

1mo agoThe Globe and Mail

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Codexis (CDXS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1mo agoYahoo Finance

Also Discussed

Investors talking about CDXS also mention

#	Name	Attention
1	Twist Bioscience CorporationTWST	0%-0.02
2	Wave Life Sciences Ltd.WVE	0%+0
3	Edap Tms S.A.EDAP	0%0
4	Cerus CorporationCERS	0%new
5	Seer, Inc. Class A Common StockSEER	0%0
6	Tilly's Inc.TLYS	0%new
7	Camtek Ltd.CAMT	0%0
8	Eaton Vance High Income Municipal ETFEVYM	0%new
9	eXoZymes Inc.EXOZ	0%0
10	Where Food Comes From, Inc.WFCF	0%0

Codexis Inc.

Healthcare
Biotechnology

Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis. Codexis develops and commercializes proprietary protein engineering technologies that create tailored enzymes for pharmaceutical manufacturing, RNA synthesis, molecular biology, diagnostics, and other life sciences applications. Its portfolio includes enzyme-based solutions, screening kits, and process development support designed to improve efficiency in complex manufacturing workflows. The company serves customers across the pharmaceutical, industrial, food, agricultural, and specialty chemicals markets, where engineered enzymes can help enable more precise and scalable production processes. Codexis also works on next-generation biotherapeutic and oligonucleotide manufacturing platforms, reflecting its role as a specialized provider of tools and technologies for modern drug development and advanced biological manufacturing. Headquartered in Redwood City, California, Codexis Inc. operates as a platform-driven company within the broader life sciences and synthetic biology market.

Website

Location

200 Penobscot Drive

Redwood City, CA, 94063

United States

Social

What share of all stock conversation is about CDXS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% 0

Aug 11

Codexis, Inc. ($CDXS) reported Q2 2026 revenue of $14.9 million, with product revenue rising to $13.2 million and legacy R&D service revenue declining.
The company expects its existing cash to be sufficient to fund operations through the end of 2028, including the build-out of a GMP production facility.
Codexis is in advanced negotiations for a long-term commercial contract with a CDMO, which could be a significant announcement by the end of the year.

Generated by AI

Sentiment

Of the messages about CDXS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0%	50%	75% -10.71	84.01% -0.67
Bearish	100%	50%	25% +10.71	15.99% +0.67

Bullish· Jun 18

Codexis, Inc. ($CDXS) has been given an $11 price target by Cantor Fitzgerald, indicating a potential double or triple in value.
The company is considered a "lottery ticket" with a high potential for growth, making it a must-own stock for investors.
A takeover or acquisition of Codexis, Inc. is expected, which could drive up the stock price and result in significant returns for investors.

Bearish· Mar 12

$CDXS is expected to fall to around $2.25, with some investors selling at $66.
The stock's price action is not real, with market makers artificially keeping the bid/ask fixed, preventing any meaningful movement.
Shorts are being squeezed, with some investors facing potential losses if they don't cover their positions ASAP, and others being warned of a "big story" or "huge failure" in the near future.

Generated by AI

Topics

Of the messages about CDXS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	50%	94.44%	94.74%	55.46%
Technical Analysis	50%	5.56%	5.26%	28.65%
Earnings	0%	0%	0%	1.7%
Analysts	0%	0%	0%	7.23%
Controversies	0%	0%	0%	0%
Macro	0%	0%	0%	6.95%

Earnings· May 10

Codexis, Inc. ($CDXS) beats earnings per share (EPS) loss estimates by $0.07.
$CDXS beats revenue estimates.
Codexis, Inc. ($CDXS) reports a positive earnings surprise.

Announcements· Mar 20

Codexis, Inc. (CDXS) announces partnership with NASDAQ:NXXT to scale intelligence across operations.
NASDAQ:NXXT aligns infrastructure with AI, driving growth and supporting energy demand, in a move that benefits CDXS.
CDXS is mentioned as a partner in NASDAQ:NXXT's growth, with both companies working together on infrastructure systems.

Generated by AI

Community

Of the messages about CDXS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	55.56%	48.39%	35.28%
Newcomers	0%	44.44%	51.61%	64.72%

Regulars· Aug 11

Codexis has completed tech transfers for all three CDMO contracts, with one in advanced negotiations for a long-term commercial partnership.
The company expects its existing cash to fund operations through 2028, including the build-out of a GMP production facility, and is optimistic about the potential for milestone payments from the lead contract.
Despite concerns about the lack of tangible revenue-driving deals, Codexis' product revenue surged in Q2 2026, masking a collapse in legacy R&D service revenue.

Newcomers· Jul 24

Newcomers to discussing Codexis, Inc. (CDXS) are focused on the company's recent stock offering, which priced 16.7 million common shares at $1.50 per share, raising approximately $23.1 million in net proceeds.
Some newcomers are concerned about the company's potential need to do a reverse split within the next six months, citing the large amount of shares issued in the offering.
Others are expressing skepticism about the company's recovery prospects, with some even predicting a potential decline in the stock price, while others are questioning the timing of the announcement.

Generated by AI

Codexis

Social

Aug 11

Bullish· Jun 18

Bearish· Mar 12

Earnings· May 10

Announcements· Mar 20

Regulars· Aug 11

Newcomers· Jul 24

Codexis partners with siRNA innovator on enzyme synthesis

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

Codexis at Cantor conference: enzymatic RNA manufacturing gains ground

Codexis to Participate in Cantor Global Healthcare Conference 2026

Codexis (CDXS) Q2 2026 Earnings Call Transcript

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Also Discussed

Codexis Inc.

Company Information

Location

Codexis partners with siRNA innovator on enzyme synthesis

Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA

Codexis at Cantor conference: enzymatic RNA manufacturing gains ground

Codexis to Participate in Cantor Global Healthcare Conference 2026

Codexis (CDXS) Q2 2026 Earnings Call Transcript

Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?

Also Discussed

Social

Aug 11

Bullish· Jun 18

Bearish· Mar 12

Earnings· May 10

Announcements· Mar 20

Regulars· Aug 11

Newcomers· Jul 24